SMFR Stock Overview
Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data.
Sema4 Holdings Corp. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.89|
|52 Week High||US$9.18|
|52 Week Low||US$0.83|
|1 Month Change||-12.35%|
|3 Month Change||-38.95%|
|1 Year Change||-87.65%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-90.97%|
Recent News & Updates
Sema4 names Kevin Feeley as CFO
Sema4 (NASDAQ:SMFR) has appointed healthcare industry veteran Kevin Feeley as CFO. Feeley has over 20 years of finance and accounting leadership experience in the healthcare, pharmaceutical, and diagnostics sectors. He has held the roles of Senior Vice President of Operations and Head of GeneDx at Sema4 since May 2022. Earlier this month, Sema4 was downgraded at Jefferies due to Q2 miss and guidance cut
Things Look Grim For Sema4 Holdings Corp. (NASDAQ:SMFR) After Today's Downgrade
Market forces rained on the parade of Sema4 Holdings Corp. ( NASDAQ:SMFR ) shareholders today, when the analysts...
Sema4 Holdings Corp. (NASDAQ:SMFR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
As you might know, Sema4 Holdings Corp. ( NASDAQ:SMFR ) last week released its latest quarterly, and things did not...
|SMFR||US Healthcare||US Market|
Return vs Industry: SMFR underperformed the US Healthcare industry which returned 7.7% over the past year.
Return vs Market: SMFR underperformed the US Market which returned -23.2% over the past year.
|SMFR Average Weekly Movement||16.4%|
|Healthcare Industry Average Movement||7.9%|
|Market Average Movement||6.8%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: SMFR is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: SMFR's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing.
Sema4 Holdings Corp. Fundamentals Summary
|SMFR fundamental statistics|
Is SMFR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SMFR income statement (TTM)|
|Cost of Revenue||US$225.87m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.45|
|Net Profit Margin||-89.01%|
How did SMFR perform over the long term?See historical performance and comparison